2024³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-08
±³À°ÀÏÀÚ : 2024-06-08
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾ÅÍ AIȦ / ÄÁÆÛ·±½º·ë 1~3
±³À°ÁÖÁ¦ : 2024³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ
´ã´çÀÚ : ÃÖÀº¿µ
¿¬¶ôó : 070-8873-6030
À̸ÞÀÏ : k-iscp@kscvp.org
±³À°Á¾·ù : ³»°ú, ½Å°æ¿Ü°ú
Âü¼®¿¹»óÀÎ : 160¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 09:00~09:20 Beta blockers/Calcium channel blockers À±¹ÎÀç(¼¿ïÀÇ´ë ¼øȯ±â³»°ú )
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 09:20~09:40 Diuretics ¾ÈÈ¿¼® (°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú )
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 09:40~10:00 Statin/Fibrate/Omega-3 fatty acid ½Åµ¿È£(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 10:00~10:20 Inotropics & Vasopressors ÃÖÁ¤Çö( ºÎ»êÀÇ´ë ¼øȯ±â³»°ú )
Åä·Ð 06¿ù 08ÀÏ AIȦ 10:20~10:30 Åä·Ð ()
ÈÞ½Ä 06¿ù 08ÀÏ 10:30~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 08ÀÏ ÄÁÆÛ·±½º·ë 1~3 10:50~11:10 It's new, but it's not new anymore: RNA-based therapeutics for CVD À§Áø (°¡ÃµÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:10~11:30 Can RNA drugs be the game changers for dyslipidemia treatement ? ¹ÚÀçÇü(°í·ÁÀÇ´ë ¼øȯ±â³»°ú )
±³À°½Ã°£ 06¿ù 08ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:30~11:50 The world's first RNA interference drug: Patisiran in ATTR amyloidosis with cardiomyopathy ±è°æÈñ (ÀÎõ¼¼Á¾º´¿ø ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ ÄÁÆÛ·±½º·ë 1~3 11:50~12:10 Are there even new RNA drugs for treating HTN ? Á¤¹ÌÇâ (°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú )
Åä·Ð 06¿ù 08ÀÏ ÄÁÆÛ·±½º·ë 1~3 12:10~12:20 Åä·Ð ()
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 10:50~11:10 Cancer induced thromboembolism È«Á¤¾Ö(ÇѸ²ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 11:10~11:30 Cancer and Heart Failure ¹ÚÁøÁÖ(¼¿ïÀÇ´ë ½ÉÀåÇ÷°ü³»°ú )
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 11:30~11:50 Chemotherapy induced Cardiovascular adverse drug reaction È«¼Ò¿¬ (ºÐ´ç¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 11:50~12:10 Role of Pharmacist in Cardio-oncoloy À¯Áö¿¬(ÇѸ²´ë¼º½Éº´¿ø ¾àÁ¦ºÎ)
Åä·Ð 06¿ù 08ÀÏ AIȦ 12:10~12:20 Åä·Ð ()
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 12:20~12:40 Integrating Artificial Intelligence into Electrocardiography: A New Era of Cardiology ¹é¿ë¼ö(ÀÎÇÏÀÇ´ë ½ÉÀå³»°ú)
½Ä»ç 06¿ù 08ÀÏ 12:40~13:30 ½Ä»ç ()
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 13:30~13:50 Overview: Current anti-obesity medication ¼Àçºó(¼¿ïÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 13:50~14:10 Weekly GLP-1 Receptor Agonist (Semaglutide) À̼¼Á¤(Â÷ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 14:10~14:30 GLP-1/GIP Dual Agonist (Tirzepatide) õ´ë¿µ(ÇѸ²ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 14:30~14:50 Upcoming drugs to conquer obesity Á¤Ã¢Èñ(¿ï»êÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 06¿ù 08ÀÏ AIȦ 14:50~15:00 Åä·Ð ()
ÈÞ½Ä 06¿ù 08ÀÏ 15:00~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 15:20~15:40 Introduction of arterial stiffness ±èÇзÉ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 15:40~16:00 Statin Á¤ÀçÈÆ(µ¿±¹ÀÇ´ë ¼øȯ±â³»°ú )
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 16:00~16:20 RAS blockers ½ÅÁ¤ÈÆ(ÇѾçÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 06¿ù 08ÀÏ AIȦ 16:20~16:40 Emerging drugs (sacubitril/valsartan and SGLT2 inhibitors) °ø¹Î±Ô(¼øõÇâÀÇ´ë ½ÉÀå³»°ú )
Åä·Ð 06¿ù 08ÀÏ AIȦ 16:50~17:00 Åä·Ð ()